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management. Each treatment option has advantages and disad-
vantages; thus individual therapy should be chosen to provide the 
maximum effect and minimum morbidity. In most cases of spi-
nal metastasis, non-surgical treatment is considered first, but it is 
difficult to achieve rapid and direct decompression of neural 
structures with non-surgical treatment. Surgical management of 
spinal metastasis is a good treatment method for rapid decom-
pression of neural structures and immediate stabilization of the 
spine. However, surgical management on spinal metastasis is still 
controversial6,14,37). General indications for surgery are spinal in-
stability, progressive symptomatic deformities, neurological defi-
cits, and intractable pain resistant to other treatments than sur-
gery. As surgery often requires a significant recovery period and 
complications can occur, the prediction of postoperative survival 
time is the most critical factor in making the decision for sur-
gery2). Therefore, several authors have tried to find factors related 
with postoperative survival time. Such efforts have been pro-
INTRODUCTION
As diagnostic techniques and treatment options have been im-
proving in cancer patients, their life expectancy has been mark-
edly extended13). Furthermore, the incidence and prevalence of 
spinal metastasis have been increasing owing to advances in 
neuroradiological imaging9). Skeletal metastasis is a frequent 
problem in cancer patients, and spinal metastases account for 
approximately 50% of bone metastases1). Approximately 10% of 
cancer patients are diagnosed with symptomatic spinal metasta-
sis during their lifetime, and up to 50% of spinal metastasis pa-
tients require treatment due to pain or neurological deficits2,12,30).
Untreated spinal metastasis results in the deterioration of life 
quality due to severe neurological deficits and intractable pain, 
which can shorten life expectancy with complications. Treatment 
options for spinal metastasis include radiation therapy, systemic 
chemotherapy, bisphosphonates, radioisotopes, and surgical 
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male. The below 55 years old group comprised 98 patients, and 
the above 56 years old group included 119 patients. The slow, 
moderate, and rapid growth tumor groups included 50, 47, and 
120 patients, respectively. With regard to histology of the prima-
ry cancer, lung cancer (45 patients) was the most common. 
Colorectal cancer (27 patients), breast cancer (24 patients), he-
patocellular carcinoma (20 patients), renal cell carcinoma (17 
patients), prostate cancer (13 patients), and thyroid cancer (12 
patients) followed (Table 1). Regarding the spinal level of in-
volvement, thoracic spinal metastasis (100 patients) was the 
most common, and lumbosacral metastasis (65 patients) and 
cervical metastasis (32 patients) followed. The remaining 20 pa-
tients’ cancers involved the cervicothoracic spine or thoracolum-
bar spine simultaneously. Radiation therapy (RT) was undertak-
en in 53 patients preoperatively, 104 patients postoperatively 
and 60 patients had no radiation therapy. In no RT group, some 
patients received chemotherapy instead of RT and the others 
did not have RT due to poor systemic condition or postopera-
tive complications.
Surgical indications in the present study were as follows : 1) 
life expectancy longer than 3 months, 2) axial or translational 
instability due to pathological fractures or tumor invasion, 3) 
progressed symptomatic spinal metastasis after non-surgical 
treatment, 4) spinal cord compression with motor weakness 
(below motor grade IV) or uncontrolled pain. 
We classified surgery type into four groups. Decompressive 
laminectomy was performed in 48 patients, decompressive 
laminectomy with posterior fixation in 40 patients, corpectomy 
with anterior fusion in 74 patients, and corpectomy with poste-
rior fixation in 55 patients. 
Preoperative systemic condition was based on the Tomita 
scoring system which evaluates the systemic extent of cancer 
with primary tumor growth rate, condition of visceral metasta-
sis, and bone metastasis35). The Tomita scores range from 2 to 10 
points and higher score means poorer systemic status. We classi-
fied all the patients into 2 groups; unfavorable vs. favorable. The 
unfavorable group comprised 137 patients (≥6 points), and the 
favorable group comprised 80 patients (≤5 points). Pre- and 
postoperative ambulatory function was divided into 2 groups; 
ambulatory and non-ambulatory. We defined ambulatory status 
as Nurick grade 1 to 4. Non-ambulatory status means Nurick 
grade 5. The preoperative ambulatory group contained 64 pa-
tients, and the non-ambulatory group comprised 153 patients. 
The postoperative ambulatory group included 179 patients, and 
the non-ambulatory group included 38 patients. The single spi-
nal metastasis group included 106 patients, and the multiple lev-
el involvement group included 111 patients. The number of pa-
tients who had postoperative complication was 46, and that of 
no complication group was 171. 
The time interval from primary cancer diagnosis to spinal me-
tastasis was divided into 2 groups. Based on a mean value of 21.3 
months, the number of patients whose period was less than 21 
months was 148, and the number of patients whose period was 
posed by Tomita et al.35), Tokuhashi et al.32,33), North et al.25), Hi-
rabayashi et al.15), Arrigo et al.2), and Moon et al.24). 
We reviewed the medical records of 217 patients from 2001 
to 2009 in our hospital to find out prognostic factors related to 
postoperative survival in spinal metastases.
MATERIALS AND METHODS
We reviewed the medical records and radiological images of 
217 patients who underwent spinal metastasis operations from 
2001 to 2009 at our hospital. The patients with multiple myelo-
ma and lymphoma were excluded because they had systemic 
hematological disease, not a metastatic spread of a solid tumor. 
We followed up spinal metastasis patients until May 2011; survi-
vors comprised 16 patients. We analyzed the prognostic factors 
we believed were related to postoperative survival times. They 
were gender, age (below 55 years old or above 56 years old groups 
based on a mean age of 55.5 years), primary tumor growth rate 
(the slow growth group involves breast cancer, prostate cancer, 
and thyroid cancer; moderate growth group involves bladder 
cancer, cervix cancer, melanoma, liposarcoma, ovarian cancer, 
osteosarcoma, nasopharyngeal carcinoma, renal cell carcinoma, 
and tongue cancer; the rapid growth group involves gastric can-
cer, cholangio-carcinoma, colorectal cancer, esophageal cancer, 
hepatocellular carcinoma, lung cancer, and masses of unknown 
origin), involved spinal location (cervical, thoracic, and lumbo-
sacral spine), the timing of radiation therapy (preoperative, post-
operative, and no radiation), operation type (decompressive 
laminectomy with or without posterior fixation, corpectomy 
with anterior fusion, and corpectomy with posterior fixation), 
preoperative systemic condition (group with Tomita score ≤5 
points, group with Tomita score ≥6 points), pre- and postopera-
tive ambulatory function (ambulatory, non-ambulatory), num-
ber of spinal metastases (single, multiple), and time to spinal 
metastasis from the primary cancer diagnosis (below 21 months 
or above 22 months, based on a mean value of 21.3 months). 
The occurrence of postoperative complications (complication, 
no complication) were also included.
In the study cohort, 128 patients were male, and 89 were fe-
Table 1. Mean time to spinal metastasis after primary tumor diagnosis
Tumor histology No. of patients Mean time (mos)
Lung Ca.    45   5.5
Colorectal Ca.    27 28.1
Breast Ca.    24  48.6
Hepatocellular Ca.    20   7.3
Renal cell Ca.    17   20.2
Prostate Ca.    13 25.2
Thyroid Ca.    12 42.8
Others*    59 19.1
Total 217 21.3
*MUO, osteosarcoma, bladder, tongue, etc. (tumor groups below 10 patients). Ca : 
cancer, mos : months 129
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Tomita score higher than 6 points was 5.0 months (95% CI : 4.1-
5.9 months). Preoperative ambulatory status also was a signifi-
cant prognostic factor; the median survival time of the walking 
group was 7.0 months (95% CI : 4.8-9.2 months), and that of 
the non-ambulatory group was 3.0 months (95% CI : 1.6-4.4 
months). Maintained ambulatory function after surgery also 
was a good prognostic factor. The median survival time was 8.0 
months (95% CI : 6.3-9.7 months) in the ambulatory group and 
1.0 month (95% CI : 0.5-1.5 months) in the non-ambulatory 
group. Age, involved spinal location, radiotherapy timing, oper-
ation type, number of spinal metastases, time to spinal metasta-
sis from the primary cancer diagnosis, and the occurrence of 
postoperative complication had no statistical significance 
(p>0.05) (Table 3). We performed logistic regressive analysis of 
the multivariate Cox proportional hazard model with signifi-
cant factors in univariate analysis (Table 4) (Fig. 1). It showed 
that preoperative systemic condition [odds ratio (OR) : 1.439, 
95% CI : 1.003-2.065, p=0.048] and postoperative ambulation 
status (OR : 5.397, 95% CI : 3.560-8.181, p<0.001) were prog-
nostic factors associated with longer postoperative survival.
Postoperative complications were found in 46 patients (21.2%). 
These included acute hematoma in 8 patients, gastrointestinal 
problems in 4 patients, infection in 20 patients, paraplegia in 1 
patient, pulmonary complications in 11 patients, and instru-
ment-related problems in 2 patients (Table 5). The one-month 
mortality rate was 14.3% (31 patients). Among 46 patients with 
postoperative complications, 12 patients belonged to the post-
operative non-ambulatory group. 
DISCUSSION
As diagnostic methods and treatment options for cancer pa-
tients have improved, their survival has been extended. There-
fore, spinal metastasis can be seen in cancer patients more fre-
quently than in the past9). As a result, management of spinal 
metastasis has become an important issue. In spinal metastasis, 
the effectiveness of surgical treatment is still controversial6,14,37). 
Progressive and untreated spinal metastasis may lead to com-
pression fracture of the vertebral body, vertebral column insta-
longer than 22 months was 69. We performed Kaplan-Meier 
analysis to estimate event-time distributions, made comparisons 
using Log-Rank statistics (Mantel-Cox with SPSS, version 14.0) 
and tested a Cox proportional hazards model to determine 
which independent factors prognosticated for postoperative sur-
vival. p-values of <0.05 were considered significant. 
RESULTS
The mean age of the study cohort at the time of spine surgery 
was 55.5 years (range 17-83 years). The mean time interval to spi-
nal metastasis after primary cancer diagnosis was 21.3 months 
(range 0-216 months). The time interval between diagnosis of 
primary cancer and spinal metastasis was a mean of 5.5 months 
(range 0-70 months) in lung cancer patients. However, the 
breast cancer group showed a mean 48.6 months (range 0-216 
months) (Table 1). The median values of overall survival times 
after spinal operation and spinal metastasis diagnosis were 6.0 
months [95% confidence interval (CI) : 4.9-7.1 months] and 9.0 
months (95% CI : 6.9-11.1 months), respectively. Thyroid cancer 
patients had the longest values, with 43.0 months (95% CI : 
0-92.2 months) after spinal operation and 57.0 months (95% CI 
: 21.7-99.4 months) after spinal metastasis diagnosis. The group 
with the shortest durations was the colorectal cancer group, with 
5.0 months (95% CI : 1.6-8.4 months) and 8.0 months (95% CI : 
1.2-8.8 months) (Table 2) after spinal metastasis diagnosis.
In univariate analysis, statistically significant factors related 
with longer postoperative survival were gender, primary tumor 
growth rate, preoperative systemic condition, and pre- and post-
operative ambulatory status (p<0.05) (Table 3). In males, the 
median survival after surgery was 5.0 months (95% CI : 3.6-6.4 
months) and 8.0 months in females (95% CI : 5.5-10.5 months). 
The median survival of the slow growing tumor group was 12.0 
months (95% CI : 2.8-21.2 months), and those of the moderate 
and rapid growth groups were 6.0 and 5.0 months (95% CIs : 
3.3-8.7 months and 3.9-6.1 months), respectively. Regarding 
preoperative systemic condition, the median survival in pa-
tients whose Tomita score was lower than 5 points was 10.0 
months (95% CI : 7.1-12.9 months), and that in patients with a 
Table 2. Median survival time after spinal operation and spinal metastasis diagnosis
Tumor histology
After spinal operation After spinal metastasis diagnosis
Median (mos) 95% CI Median (mos)  95% CI
Lung Ca.   5.0  2.8-7.2   8.0     4.7-11.3
Colorectal Ca.   5.0  1.6-8.4   5.0   1.2-8.8
Breast Ca.   8.0    3.2-12.8 14.0     1.5-26.5
Hepatocellular Ca.   5.0  3.6-6.4   8.0        0-16.8
Renal cell Ca.   5.0  3.7-6.3   9.0     2.3-15.7
Prostate Ca. 16.0    5.4-26.6 17.0     6.4-27.6
Thyroid Ca. 43.0       0-92.2 57.0   14.6-99.4
Others*   6.0  4.5-7.5   8.0     5.5-10.5
Total   6.0  4.9-7.1   9.0     6.9-11.1
*MUO, osteosarcoma, bladder, tongue, etc. (tumor groups below 10 patients). Ca. : cancer, CI : confidence interval, mos : months 130
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to expect a rapid and direct decompression of neural structures 
with non-surgical treatment methods. Surgery is undoubtedly 
the best treatment option for rapid decompression of spinal 
neural structures and immediate stabilization of the spine31). In 
recent studies, the effectiveness of surgical treatment has been 
validated7,8,11,16,18,21,27). These articles assert that surgery could im-
bility, pain due to the nerve root and spinal cord, and significant 
neurological deficits19). In severe cases, it may cause quadriple-
gia, paraplegia, and urinary incontinence and can also shorten 
survival with complications. Non-surgical treatment methods 
are suitable for patients who are ambulatory, who have minimal 
neurological deficits, or who have pain. However, it is difficult 
Table 3. Univariate analysis of factors related to postoperative survival time
Prognostic factors
  Variable No. of patients Median survival 
(mos) 95% CI (mos) p value
Gender    0.003*
   Male 128 5.0 3.6-6.4
   Female   89 8.0   5.5-10.5
Age (years)  0.067
    Below 55   98 5.0 3.9-6.1
    Above 56 119 7.0 4.7-9.3
Primary tumor growth rate <0.001*
   Slow   50 12.0   2.8-21.2
   Moderate   47 6.0 3.3-8.7
   Rapid 120 5.0 3.9-6.1
Involved spinal location  0.725
    Cervical   32 4.0       0-10.6
    Thoracic 100 6.0 4.7-7.3
    Lumbosacral   65 8.0   5.1-10.9
Radiation therapy timing  0.470
    Preoperative   53 5.0 3.4-6.6
    Postoperative 104 7.0 4.8-9.2
    No radiation therapy   60 5.0 3.8-6.2
Operation type  0.129
   Decompressive laminectomy without posterior fixation   48 5.0 2.7-7.3
   Decompressive laminectomy with posterior fixation   40 9.0   6.5-11.5
   Corpectomy with anterior fusion   74 5.0 4.1-5.9
   Corpectomy with posterior fixation   55 7.0 4.9-9.1
Preoperative systemic condition <0.001*
   Favorable (Tomita score below 5 points)   80 10.0   7.1-12.9
   Unfavorable (Tomita score above 6 points) 137 5.0 4.1-5.9
Preoperative ambulation status   0.004*
   Ambulatory status   64 7.0 4.8-9.2
   Non-ambulatory status 153 3.0 1.6-4.4
Postoperative ambulation status  <0.001*
   Ambulatory status 179 8.0 6.3-9.7
   Non-ambulatory status   38 1.0 0.5-1.5
Number of involved spine  0.211
   Single 106 7.0 4.5-9.5
   Multiple 111 5.0 3.4-6.6
Time to spinal metastasis from primary cancer diagnosis  0.845
   Below 21 mos 148 5.0 3.3-6.7
   Above 22 mos   69  7.0 4.8-9.2
Postoperative complication status  0.581
   Complications   46 4.0 2.0-6.0
   No complication 171 7.0 5.7-8.3
*Significant at p<0.05. CI : confidence interval, mos : months 131
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weight. It also suggested treatment strategies for spinal metasta-
sis ranging from wide or marginal excision to supportive care 
according to Tomita’s score and the treatment goal. Tokuhashi 
et al.32,33) suggested another scoring system and subsequently is-
sued a revised system. Six factors, such as general condition, ex-
prove quality of remaining life with maintained ambulatory func-
tion, and en bloc resection of a solitary spinal metastasis in-
creases the survival rate. However, surgery can cause dangerous 
complications leading to significant morbidity and mortality. 
Furthermore, some complications involve prolonged recovery 
time and could delay adjuvant therapy. Therefore, we have to 
consider life expectancy after spinal metastasis surgery in the 
selection of surgical candidates.
Several studies have attempted to investigate prognostic factors 
for survival outcome after spinal metastasis surgery2,15,24,25,32,33,35). 
Popular scoring systems for the evaluation of preoperative sys-
temic condition were suggested by Tomita and Tokuhashi. The 
Tomita scoring system is scored by primary tumor growth rate, 
condition of visceral metastasis, and bone metastasis35). In this 
report, these factors had statistical significance and different 
Table 4. Multivariate analysis of factors related to postoperative survival time
Prognostic factors
   Variable Odds ratio 95% CI p value
Gender
   Male 1.170 0.866-1.582  0.306
   Female    1
Primary tumor growth rate 0.065
   Slow    1
   Moderate 1.155 0.741-1.801  0.525
   Rapid 1.607 1.046-2.469  0.030
Preoperative systemic condition
   Favorable (Tomita score below 5 points)    1
   Unfavorable (Tomita score above 6 points) 1.439 1.003-2.065   0.048*
Preoperative ambulation status
   Ambulatory status    1
   Non-ambulatory status 1.078 0.755-1.539 0.680
Postoperative ambulation status
   Ambulatory status    1
   Non-ambulatory status 5.397 3.560-8.181 <0.001*
*Significant at p<0.05. CI : confidence interval 
Table 5. Postoperative complications
Complication type Number
Acute hematoma  8
Gastrointestinal problems  4
Infection 20
Paraplegia   1
Pulmonary problems 11
Instrument related problems   2
Total 46
Fig. 1. A : Survival curve of the groups with different preoperative systemic conditions. B : Survival curve of the groups with different postoperative 
ambulatory statuses.
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py group (54-62%) compared with the radiotherapy only group 
(19-26%)18,27).
In the present study, 115 preoperative non-ambulatory pa-
tients (75.2%) regained ambulatory function after surgery. Fac-
tors related to postoperative ambulatory function were investi-
gated in some reports18,27). North et al.25) found risk factors 
related with the loss of postoperative ambulation, including loss 
of preoperative ambulatory ability, recurrent or persistent dis-
ease after primary radiotherapy of the operative site, a procedure 
other than corpectomy, and tumor type other than breast can-
cer18,27). Patchell et al.27) reported surgery and the pretreatment 
Frankel score to be associated with longer ambulatory time18).
Gender, which was not significant in other reports, was a sig-
nificant factor for postoperative survival in univariate analy-
sis2,15,25). The reason may be the difference in the composition of 
primary cancer histologies between male and female patients. 
The proportion of the rapid growth tumor group was higher in 
male patients (65.6%, 84/128 patients) than in the female (43.8%, 
36/89 patients). In multivariate analysis, gender proved to be sta-
tistically insignificant. 
Primary cancer histology can affect postoperative survival in 
spinal metastasis because it determines the aggressiveness of spi-
nal metastasis and response to treatment3,15). Thyroid cancer, 
prostate cancer, and breast cancer are included in the slow grow-
ing tumor groups2,15,25,32,33,35). Median survival times of spinal me-
tastasis according to tumor histology were reported as 2.9-4.7 
months in lung cancer, 4.1-6.9 months in colorectal cancer, 21.0-
27.1 months in breast cancer, and 6.2 months in hepatocellular 
carcinoma, in previous articles2,5,17,26,29). In the present study, 
postoperative survival was different according to the primary tu-
mor growth rate, but statistical significance was not found.
Regarding the spinal level of involvement, the median surviv-
al after surgery of the cervical spinal metastasis group was 4.0 
months. The median survival times of the thoracic spinal me-
tastasis and lumbosacral metastasis groups were 6.0 and 8.0 
months, respectively. In general, metastases to the cervical 
spine are known as having worse prognoses than thoracic and 
lumbosacral metastases because many anatomical structures 
like the esophagus, trachea, vessels, and nerves are located 
around the cervical spine and frequently injured intraoperative-
ly22,23,28). However, the involved spinal location had no statistical 
significance in our series. 
The median survival time after surgery of the postoperative 
RT group (7.0 months) was shown to be longer than the no RT 
or preoperative RT groups (5.0 months, respectively). The pa-
tients in the preoperative RT group were in a more progressed 
state at the time of surgery than the patients in the postopera-
tive RT group because the surgically removed metastasis had 
been already irradiated as an initial treatment. 
CONCLUSION
As diagnostic tools and treatment methods have improved, 
tra-spinal metastasis, number of vertebral body metastases, grade 
of major internal organ metastasis, primary cancer type, and level 
of palsy comprise their scoring system. The factors which com-
prise the Tomita scoring system are also included in the Toku-
hashi scoring system. However, several differences are present 
between the two scoring systems. Tomita emphasized the grade 
of primary tumor growth rate and visceral metastasis; however, 
Tokuhashi placed more weight on the primary tumor growth 
rate. Colorectal cancer belongs to the rapid tumor growth group 
in Tomita’s classification, but it is included in the good prognosis 
group in Tokuhashi’s classification. North et al.25) also analyzed 
prognostic factors related with postoperative survival time. They 
evaluated multiple factors, such as tumor type, gender, age, pre-
operative ambulatory grade, continence, radiotherapy, type of 
surgery, and number of compressed spinal levels, etc. In their 
study, statistically significant prognostic factors for reduced sur-
vival were surgical intervention extending over two or more spi-
nal segments, recurrent or persistent disease after primary ra-
diotherapy involving the operative site, diagnosis other than 
breast cancer, and a cervical spinal procedure. Hirabayashi et 
al.15) identified anatomic sites of primary cancer and postopera-
tive ambulation were associated with longer survival after palli-
ative spinal surgery. Arrigo et al.2) confirmed that primary tumor 
type, radio-sensitivity of the tumor and preoperative ambulatory 
status were significant predictors of survival. Moon et al.24) found 
significant factors related with survival were preoperative East-
ern Cooperative Oncology Group performance status and To-
mita score.
However, most of these studies had a small sample design (less 
than 100 patients) except for the studies by Arrigo and Moon et 
al. In our study cohort of 217 patients, the median survival time 
after spinal operation was 6.0 months. This value is shorter than 
that of other published reports, which ranged from 7 to 14 
months7,10,15,20,25,34,36). In the present study, patients with Tomita 
scores from 8 to 10 comprised 25.3% (55 patients), and 55.3% 
(120 patients) belonged to the rapid growth tumor group. Pa-
tients with poor general condition and rapid growth tumors 
were associated with short postoperative survival.
In multivariate analysis, preoperative systemic condition and 
postoperative ambulation status were significant factors. Be-
tween these two factors, postoperative ambulatory function was 
the more powerful prognostic factor (p<0.001)4,11,15). For this 
reason, if some patients have a chance to recover their ambula-
tory function, more aggressive surgical management is recom-
mended. In recent studies on spinal metastasis treatment, it is 
known that direct decompressive surgery with postoperative 
radiotherapy is superior to treatment with radiotherapy alone 
in terms of post-treatment survival18,27). According to the results 
with regard to postoperative ambulation, the surgery with or 
without postoperative radiotherapy group (84%) had better re-
sults compared with the radiotherapy only group (57-64%). 
Furthermore, the chance to regain ambulatory function was 
higher in the surgery with or without postoperative radiothera-133
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the number of spinal metastasis patients has increased. The 
management of spinal metastasis patients is a very difficult 
problem. Predicting postoperative life expectancy is an impor-
tant factor for selecting the appropriate treatment method. In 
the present study cohort of 217 patients, the overall median 
survival was 6.0 months following the spine metastasis opera-
tion. Preoperative systemic condition and postoperative ambu-
latory status were statistically significant for postoperative sur-
vival time. 
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